Last reviewed · How we verify
ILX23-7553
At a glance
| Generic name | ILX23-7553 |
|---|---|
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- ILX23-7553 in Treating Patients With Solid Tumors That Have Not Responded to Previous Therapy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |